As expected, we found that low-risk patients were more likely to respond to immunotherapy than high-risk ones, indicating that this risk model based on immune indexes (i.e., cluster of differentiation 274/programmed cell death ligand 1 (CD274/PD-L1) carcinoma-associated fibroblasts (CAFs)) might serve as an indicator for predicting tumor immune dysfunction and exclusion (TIDE), excluding tumor-associated macrophages (Figure 6E). The gene discussed is CD274; the disease is neoplasm.